Subgroup Differences in Response to 8Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C

Treatment of hepatitis C virus (HCV) infection with ledipas-vir/sofosbuvir promises tremendous benefits, but high cost may impede implementation of this regimen. Subgroups with excellent response to 8 weeks of treatment might re-spond to a shorter course. In ION-3, 423 previously untreat-ed HCV genotype 1-infected patients without cirrhosis had outcome data after receiving ledipasvir/sofosbuvir for 8 weeks. After reanalyzing published ION-3 data, we found that sustained virologic response (SVR) rates varied significantly by gender (P =.002) and rs12979860 genotype (Ptrend =.03), exceeding 98 % in women and rs12979860-CC individuals. The very high SVR rates in these subgroups suggest that these factors might be considered in selecting patients to re-ceive 8 weeks of ledipasvir/sofosbuvir and support shorter trials of this regimen in selected patients